Cargando…
Infigratinib: First Approval
Infigratinib (TRUSELTIQ(TM)), a fibroblast growth factor receptor (FGFR)-specific tyrosine kinase inhibitor, is being co-developed by QED Therapeutics and Helsinn for the treatment of cholangiocarcinoma, urothelial carcinoma and other FGFR-driven conditions. Infigratinib was recently approved in the...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610935/ https://www.ncbi.nlm.nih.gov/pubmed/34279850 http://dx.doi.org/10.1007/s40265-021-01567-1 |